- Home
- SEER vs RDIB Comparison
SEER vs RDIB Comparison
Compare SEER & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- RDIB
- Stock Information
- Founded
- SEER 2017
- RDIB 1937
- Country
- SEER United States
- RDIB United States
- Employees
- SEER N/A
- RDIB N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- RDIB Movies/Entertainment
- Sector
- SEER Health Care
- RDIB Consumer Discretionary
- Exchange
- SEER Nasdaq
- RDIB Nasdaq
- Market Cap
- SEER 121.8M
- RDIB 140.2M
- IPO Year
- SEER 2020
- RDIB N/A
- Fundamental
- Price
- SEER $1.92
- RDIB $10.55
- Analyst Decision
- SEER Hold
- RDIB
- Analyst Count
- SEER 1
- RDIB 0
- Target Price
- SEER $3.00
- RDIB N/A
- AVG Volume (30 Days)
- SEER 455.4K
- RDIB 6.0K
- Earning Date
- SEER 05-13-2025
- RDIB 06-06-2025
- Dividend Yield
- SEER N/A
- RDIB N/A
- EPS Growth
- SEER N/A
- RDIB N/A
- EPS
- SEER N/A
- RDIB N/A
- Revenue
- SEER $15,309,000.00
- RDIB $205,644,000.00
- Revenue This Year
- SEER $26.65
- RDIB $9.74
- Revenue Next Year
- SEER $29.42
- RDIB $6.39
- P/E Ratio
- SEER N/A
- RDIB N/A
- Revenue Growth
- SEER N/A
- RDIB N/A
- 52 Week Low
- SEER $1.56
- RDIB $5.78
- 52 Week High
- SEER $2.63
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- SEER 44.16
- RDIB 51.21
- Support Level
- SEER $2.04
- RDIB $9.30
- Resistance Level
- SEER $2.07
- RDIB $11.35
- Average True Range (ATR)
- SEER 0.12
- RDIB 1.09
- MACD
- SEER -0.01
- RDIB -0.14
- Stochastic Oscillator
- SEER 16.16
- RDIB 27.23
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.